IL17F Matched Antibody Pair (619) (APMAB-619LY)

Tam, H. K. J., Robinson, P. C., & Nash, P. (2022). Inhibiting IL-17A and IL-17F in rheumatic disease: Therapeutics help to elucidate disease mechanisms. Current Rheumatology Reports, 24(10), 310-320.

Braga, M., Lara-Armi, F. F., Neves, J. S. F., Rocha-Loures, M. A., Terron-Monich, M. D. S., Bahls-Pinto, L. D., ... & Visentainer, J. E. L. (2021). Influence of IL10 (rs1800896) polymorphism and TNF-α, IL-10, IL-17A, and IL-17F serum levels in ankylosing spondylitis. Frontiers in immunology, 12, 653611.

Iznardo, H., & Puig, L. (2021). Dual inhibition of IL-17A and IL-17F in psoriatic disease. Therapeutic Advances in Chronic Disease, 12, 20406223211037846.

Adams, R., Maroof, A., Baker, T., Lawson, A. D., Oliver, R., Paveley, R., ... & Griffiths, M. (2020). Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Frontiers in Immunology, 11, 1894.

Goepfert, A., Lehmann, S., Blank, J., Kolbinger, F., & Rondeau, J. M. (2020). Structural analysis reveals that the cytokine IL-17F forms a homodimeric complex with receptor IL-17RC to drive IL-17RA-independent signaling. Immunity, 52(3), 499-512.

Gao, S., Mao, C., Cheng, J., Deng, Q., & Sheng, W. (2020). Association of IL‐17A‐197G/A and IL‐17F‐7488T/C polymorphisms and osteoarthritis susceptibility: A meta‐analysis. International Journal of Rheumatic Diseases, 23(1), 37-46.

Burns, L. A., Maroof, A., Marshall, D., Steel, K. J., Lalnunhlimi, S., Cole, S., ... & Taams, L. S. (2020). Presence, function, and regulation of IL‐17F‐expressing human CD4+ T cells. European Journal of Immunology, 50(4), 568-580.

Chen, Y., Chen, Y., Cao, P., Su, W., Zhan, N., & Dong, W. (2020). Fusobacterium nucleatum facilitates ulcerative colitis through activating IL‐17F signaling to NF‐κB via the upregulation of CARD3 expression. The Journal of pathology, 250(2), 170-182.

Glatt, S., Baeten, D., Baker, T., Griffiths, M., Ionescu, L., Lawson, A. D., ... & Shaw, S. (2018). Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Annals of the rheumatic diseases, 77(4), 523-532.

Tang, C., Kakuta, S., Shimizu, K., Kadoki, M., Kamiya, T., Shimazu, T., ... & Iwakura, Y. (2018). Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota. Nature Immunology, 19(7), 755-765.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Mouse Anti-IL17F Recombinant Antibody (B-C52)

Mouse Anti-IL17F Recombinant Antibody (4H450)

Mouse Anti-IL17F Recombinant Antibody (4H450.1)

Mouse Anti-IL17F Recombinant Antibody (1E5)

Mouse Anti-IL17F Recombinant Antibody (CBYY-I0290)

Rabbit Anti-IL17F Recombinant Antibody (CBYY-I1050)

Mouse Anti-IL17F Recombinant Antibody (CBYY-I0792)

Mouse Anti-IL17F Recombinant Antibody (CBYY-I0380)

Mouse Anti-IL17F Recombinant Antibody (CBFYM-1145)

Rabbit Anti-IL17F Recombinant Antibody (CBYY-I1666)

Isotype control